Intra-Cellular Therapies Inc. (NASDAQ:ITCI)’s share price fell 0.7% during mid-day trading on Friday . The company traded as low as $39.96 and last traded at $40.36, with a volume of 89,376 shares. The stock had previously closed at $40.63.

A number of research firms recently issued reports on ITCI. Leerink Swann reissued a “buy” rating and set a $95.00 price target on shares of Intra-Cellular Therapies in a report on Thursday, August 11th. Cowen and Company reissued a “buy” rating and set a $75.00 price target on shares of Intra-Cellular Therapies in a report on Friday, August 5th. Zacks Investment Research lowered Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a report on Wednesday, July 6th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and set a $57.00 price target on shares of Intra-Cellular Therapies in a report on Wednesday, June 22nd. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $70.78.

The firm’s 50 day moving average price is $40.87 and its 200 day moving average price is $35.67. The firm’s market cap is $1.75 billion.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.08. The firm earned $0.23 million during the quarter, compared to analyst estimates of $0.02 million. During the same quarter in the prior year, the firm earned ($0.61) EPS. The business’s quarterly revenue was up 283.3% compared to the same quarter last year. On average, equities research analysts forecast that Intra-Cellular Therapies Inc. will post ($3.17) earnings per share for the current fiscal year.

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.